Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Ragweed-SPIRE in Asthma and Ragweed Allergy
NCT02061670Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Jan 2014
- Primary completion
- Oct 2014
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ragweed-spire in ragweed allergy (3 arms), sponsored by NIOX Group. Primary endpoint: Number of subjects with adverse events at 22 weeks. Started Jan 2014; status: completed.
02
Drugs
ragweed-spire
03
Conditions
ragweed allergy
Beyond the preview
Go deeper on NCT02061670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061670.